EGFR mutation | Age ≤50 years | Age >50 years | Total | EGFR-TKI response |
G719A | 2 | 1 | 3 | 2 PR, 1 PD |
G719D | 0 | 1 | 1 | 1 PD |
G719S | 1 | 0 | 1 | 1 PR |
L747P | 0 | 2 | 2 | 1 PR, 1 PD |
A763_Y764 ins FQEA | 2 | 0 | 2 | 1 PR, 1 PD |
A767–V769 dup ASV | 0 | 4 | 4 | 4 PD |
S768–D770 dup SVD | 1 | 3 | 4 | 1 SD, 3 PD |
V769_D770 ins GSV | 1 | 0 | 1 | 1 PD |
D770_N771 ins G | 1 | 0 | 1 | 1 PD |
Del D770 ins GY | 0 | 1 | 1 | 1 PD |
Del N771 ins KH | 0 | 1 | 1 | 1 PD |
P772–773H dup PH | 0 | 1 | 1 | 1 PD |
P772_H773 ins YNP+H773Y | 1 | 0 | 1 | 1 PD |
K806E | 0 | 1 | 1 | 1 PR |
R831H | 1 | 0 | 1 | 1 PR |
L861P | 0 | 1 | 1 | 1 PR |
L861Q | 0 | 5 | 5 | 2 PR, 2 SD, 1 PD |
L861R | 0 | 1 | 1 | 1 PR |
G719A+S720F | 0 | 1 | 1 | 1 PR |
G719A+S768I | 0 | 1 | 1 | 1 PD |
G719A+V769M | 1 | 0 | 1 | 1 PD |
G719C+S768I | 0 | 1 | 1 | 1 PR |
G719D+L861Q | 0 | 1 | 1 | 1 PD |
G719S+Q701L+I706T | 0 | 1 | 1 | 1 PR |
G719S+E709K | 0 | 1 | 1 | 1 PR |
G719S+L747S | 0 | 1 | 1 | 1 PR |
G719S+L861Q | 1 | 0 | 1 | 1 PR |
P772_H773insYNP+H773Y | 1 | 0 | 1 | 1 PD |
Del-19+K754T | 0 | 1 | 1 | 1 PR |
Del-19+V769M | 0 | 1 | 1 | 1 PD |
L858R+E709A | 1 | 0 | 1 | 1 PR |
L858R+E709G | 1 | 3 | 4 | 3 PR, 1 PD |
L858R+K754R+E762K | 0 | 1 | 1 | 1 PR |
L858R+S768I | 1 | 1 | 2 | 2 PR |
L858R+R776H | 0 | 2 | 2 | 2 PR |
L858R+V834L | 1 | 3 | 4 | 2 PR, 2 PD |
L858R+A859S | 0 | 1 | 1 | 1 PR |
L858R+K860I | 1 | 0 | 1 | 1 PR |
L858R+A871E | 1 | 0 | 1 | 1 PR |
L861Q+E746G | 0 | 1 | 1 | 1 PR |
L861Q+R776H | 0 | 1 | 1 | 1 PD |
L861R+R831C | 0 | 1 | 1 | 1 PR |
Data are presented as n. EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; PR: partial response; SD: stable disease; PD: progressive disease.